Clinical trial
Safety of Lopinavir/Ritonavir (Kaletra) in HIV/HCV Co-infected Subjects vs…
NCT00234975 · AbbVie (prior sponsor, Abbott), Industry · Completed
Key facts
| NCT number | NCT00234975 |
|---|---|
| Title | Safety of Lopinavir/Ritonavir (Kaletra) in HIV/HCV Co-infected Subjects vs Baseline Liver Biopsy Metavir Score |
| Official title | Evaluation of Clinical Response and Safety in HIV Positive Subjects Co-infected With Hepatitis C Treated With a Kaletra Containing HAART Regimen |
| Lead sponsor | AbbVie (prior sponsor, Abbott), Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | HIV Infection |
| Intervention type | Drug |
| Interventions | Lopinavir/Ritonavir |
| Enrollment | 86 |
| Start date | Oct 1, 2002 |
| Primary completion | Jan 1, 2008 |
| Completion | Jan 1, 2008 |
| First posted | Oct 10, 2005 |
| Last update posted | Jan 3, 2013 |
| Countries | Puerto Rico |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: